GAITHERSBURG, Md., Nov. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novavax can ...

Feb 26 (Reuters) - Novavax ⁠raised ⁠its adjusted revenue forecast for ⁠2026 on Thursday, banking on milestone payments from ...

A Maryland biotech raised its revenue guidance for the year, thanks largely to some hefty pharma deals it’s betting will pay off.

・Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...

US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new restrictions on the jab, the pharmaceutical company announced Monday. The US drug ...

Novavax signed a potentially lucrative deal with a pharmaceutical giant. However, the biotech's core business remains uncertain. There is also plenty of risk with the company's pipeline candidates. 10 ...

Sanofi is leading commercialization efforts for Nuvaxovid and Novavax is eligible to receive ongoing tiered royalties from sales of the vaccine. A full 12-month commercial cycle under Sanofi’s control ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its GAAP profit of $0.11 ...